Financial Results, Regulatory Approval, Stock Price Update, and Conference Participation - Research Report on Hologic, Edwards Lifesciences, Hospira, PAREXEL, and Sirona Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, November 12, 2013 NEW YORK, November 12, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Hologic, Inc. (NASDAQ: HOLX Edwards Lifesciences Corp (NYSE: EW), Hospira, Inc. (NYSE: HSP), PAREXEL International Corporation (NASDAQ: PRXL), and Sirona Dental Systems, Inc. (NASDAQ: SIRO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Hologic, Inc. Research Report On November 7, 2013, Hologic, Inc. (Hologic) announced that the U.S. Food and Drug Administration (FDA) has approved the Aptima HPV 18/45 genotype assay for use on the Company's fully automated Panther system. According to the Company, it is the first test to be approved by FDA for genotyping human papillomavirus (HPV) types 16, 18 and/or 45. The Aptima HPV 16 18/45 genotype assay is performed using Hologic's ThinPrep liquid cytology specimen and is intended to be tested from the same sample that has already received Aptima HPV assay positive results. "The addition of the Aptima HPV 16 18/45 genotype assay to the Panther menu further extends the capability of low- to high-volume laboratories to run multiple tests from a single specimen, on a cost-effective, highly flexible and fully automated molecular testing platform," said Rohan Hastie, Ph.D., Hologic's Group's Vice President - Diagnostics. The Full Research Report on Hologic, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/d132_HOLX] -- Edwards Lifesciences Corp Research Report On November 7, 2013, Edwards Lifesciences Corp's (Edwards Lifesciences) stock rose 1.68% to close the day $63.61. Over the past three trading sessions, Edward Lifesciences' stock rallied 0.57%, compared to the Dow Jones Industrial Average Index, which fell 0.29% during the same period. The Full Research Report on Edwards Lifesciences Corp - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/48b8_EW] -- Hospira, Inc. Research Report On November 6, 2013, Hospira, Inc. (Hospira) reported its Q3 2013 financial results with net sales of $1.0 billion, up 1.4% YoY. Hospira's adjusted income from operations increased 8.3% YoY to $122 million in Q3 2013, driven by favorable product mix compared to Q3 2012 as well as supply recovery in the United Sates, which more than offset increase in selling, general and administrative expense on YoY basis. Commenting on the results, Hospira's CEO F. Michael Ball stated, "The third quarter was one of continued progress in several areas. We were especially pleased to receive European approval in the quarter of our biosimilar infliximab, Inflectra™ - the first monoclonal antibody biosimilar to be approved in Europe. We are also seeing continued demand for the new premix versions of our branded sedation agent, Precedex™. At the same time, we have made meaningful advances in both our supply recovery efforts and quality-improvement initiatives. We believe our progress across these fronts is positioning Hospira for a stronger, more competitive future, which we believe will provide sustainable, long-term growth and value to our shareholders." The Full Research Report on Hospira, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/1f43_HSP] -- PAREXEL International Corporation Research Report On November 7, 2013, PAREXEL International Corporation (PAREXEL) announced its participation at the upcoming Goldman Sachs Emerging Growth Conference, to be held in New York, on Thursday, November 14, 2013 at 11:20 a.m. ET. The Company informed that during the presentation PAREXEL's Chairman and CEO, Josef von Rickenbach will discuss about the business developments of the Company. According to the Company, a live webcast of the presentation will be available at PAREXEL's website. The Full Research Report on PAREXEL International Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/067b_PRXL] -- Sirona Dental Systems, Inc. Research Report On November 7, 2013, Sirona Dental Systems, Inc.'s (Sirona) stock ended the day 0.89% lower to $71.65. Over the past three trading sessions, Sirona's stock fell 1.12% compared to the NASDAQ composite index, which declined 2.01% during the same period. The Full Research Report on Sirona Dental Systems, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/08e7_SIRO] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
U.K. August Inflation Slows to 1.5%, Matching Median Estimate
Financial Results, Regulatory Approval, Stock Price Update, and Conference Participation - Research Report on Hologic, Edwards
Press spacebar to pause and continue. Press esc to stop.